4,851 Shares in AbbVie Inc. $ABBV Purchased by Investment Research Partners LLC

Investment Research Partners LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 4,851 shares of the company’s stock, valued at approximately $1,092,000.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $4,288,200,000. Wellington Management Group LLP increased its stake in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC raised its position in AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its stake in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research analyst reports. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Morgan Stanley raised their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Evercore lowered their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year collaboration with AbbVie to advance a next‑generation antibody discovery platform, providing upfront and milestone payments and potential pipeline upside. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Legendary investor Ken Fisher has AbbVie among notable portfolio moves for 2026, signaling continued institutional interest that can support the stock over the medium term. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Positive Sentiment: Zacks highlights AbbVie as a strong value pick based on style scores and fundamentals, which may attract value-oriented buyers amid short‑term weakness. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: Technically, ABBV slipped below its 50‑day moving average, signaling short‑term weakness to traders but it remains above the 200‑day average, so the long‑term trend is intact. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Neutral Sentiment: Market commentary (MSN/Benzinga) notes the share move largely reflects competitor progress rather than new AbbVie-specific fundamentals—useful for context but not new company data. What’s Going On With AbbVie Stock Today?
• Neutral Sentiment: High‑level policy reporting shows TrumpRx price lists aren’t uniformly cheaper than the UK, a reminder of ongoing pricing and regulatory scrutiny in pharma but not an AbbVie‑specific action today. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: FDA approved J&J’s oral IL‑23 inhibitor (Icotyde), the first oral peptide that blocks IL‑23 and a direct competitive threat to Skyrizi/Tremfya; J&J expects this class could reach blockbuster sales, increasing pressure on AbbVie’s pricing and market share in psoriasis. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: several outlets report ABBV shares fell sharply today after the J&J approval, indicating investor concern about near‑term revenue impact for Skyrizi. AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
• Negative Sentiment: Legal risk: a U.S. appeals court revived a whistleblower suit accusing big drugmakers of overcharging programs for low‑income patients, reviving potential litigation and settlement exposure for major pharma names. Big drugmakers must face US overcharge claims on medications for low-income patients

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $208.47 on Thursday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market capitalization of $368.62 billion, a PE ratio of 88.34, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. The company has a fifty day moving average of $223.76 and a 200-day moving average of $224.84.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the business posted $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.